- Volume 17 Issue 7
DOI QR Code
35-Year Research History of Cytotoxicity and Cancer: a Quantitative and Qualitative Analysis
- Farghadani, Reyhaneh (Department of Molecular Medicine,Faculty of Medicine, University of Malaya,Kuala Lumpur) ;
- Haerian, Batoul Sadat (Faculty of Medicine, Shahid Beheshti University of Medical Sciences) ;
- Ebrahim, Nader Ale (Research Support Unit, Centre for Research Services, Institute of Research Management and Monitoring (IPPP), University of Malaya) ;
- Muniandy, Sekaran (Department of Molecular Medicine,Faculty of Medicine, University of Malaya,Kuala Lumpur)
- Published : 2016.07.01
Cancer is the leading cause of morbidity and mortality worldwide, characterized by irregular cell growth. Cytotoxicity or killing tumor cells that divide rapidly is the basic function of chemotherapeutic drugs. However, these agents can damage normal dividing cells, leading to adverse effects in the body. In view of great advances in cancer therapy, which are increasingly reported each year, we quantitatively and qualitatively evaluated the papers published between 1981 and December 2015, with a closer look at the highly cited papers (HCPs), for a better understanding of literature related to cytotoxicity in cancer therapy. Online documents in the Web of Science (WOS) database were analyzed based on the publication year, the number of times they were cited, research area, source, language, document type, countries, organization-enhanced and funding agencies. A total of 3,473 publications relevant to the target key words were found in the WOS database over 35 years and 86% of them (n=2,993) were published between 2000-2015. These papers had been cited 54,330 times without self-citation from 1981 to 2015. Of the 3,473 publications, 17 (3,557citations) were the most frequently cited ones between 2005 and 2015. The topmost HCP was about generating a comprehensive preclinical database (CCLE) with 825 (23.2%) citations. One third of the remaining HCPs had focused on drug discovery through improving conventional therapeutic agents such as metformin and ginseng. Another 33% of the HCPs concerned engineered nanoparticles (NPs) such as polyamidoamine (PAMAM) dendritic polymers, PTX/SPIO-loaded PLGAs and cell-derived NPs to increase drug effectiveness and decrease drug toxicity in cancer therapy. The remaining HCPs reported novel factors such as miR-205, Nrf2 and p27 suggesting their interference with development of cancer in targeted cancer therapy. In conclusion, analysis of 35-year publications and HCPs on cytotoxicity in cancer in the present report provides opportunities for a better understanding the extent of topics published and may help future research in this area.
Supported by : University Malaya
- Airley RE, Mobasheri A (2007). Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy, 53, 233-56. https://doi.org/10.1159/000104457
- Barretina J, Caponigro G, Stransky N, et al (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 483, 603-7. https://doi.org/10.1038/nature11003
- Chu IM, Hengst L, Slingerland JM (2008). The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature Reviews Cancer, 8, 253-67. https://doi.org/10.1038/nrc2347
- Cooper G (2000). The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. Development and Causes of Cancer.
- Corrie PG (2008). Cytotoxic chemotherapy: clinical aspects. Med, 36, 24-8. https://doi.org/10.1016/j.mpmed.2007.10.012
- Deeb KK, Trump DL, Johnson CS (2007). Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews Cancer, 7, 684-700. https://doi.org/10.1038/nrc2196
- Deng ZJ, Morton SW, Ben-Akiva E, et al (2013). Layer-bylayer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS nano, 7, 9571-84. https://doi.org/10.1021/nn4047925
- DeSantis CE, Lin CC, Mariotto AB, et al (2014). Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin, 64, 252-71. https://doi.org/10.3322/caac.21235
- Dong K, Liu Z, Li Z, et al (2013). Hydrophobic anticancer drug delivery by a 980 nm laser-driven photothermal vehicle for efficient synergistic therapy of cancer cells In Vivo. Advanced Materials, 25, 4452-8. https://doi.org/10.1002/adma.201301232
- Fang RH, Hu C-MJ, Luk BT, et al (2014). Cancer cell membranecoated nanoparticles for anticancer vaccination and drug delivery. Nano letters, 14, 2181-8. https://doi.org/10.1021/nl500618u
- Foldbjerg R, Dang DA, Autrup H (2011). Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Archives of toxicol, 85, 743-50. https://doi.org/10.1007/s00204-010-0545-5
- Heiser LM, Sadanandam A, Kuo WL, et al (2012). Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings National Academy Sci, 109, 2724-9. https://doi.org/10.1073/pnas.1018854108
- Homma S, Ishii Y, Morishima Y, et al (2009). Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res, 15, 3423-32. https://doi.org/10.1158/1078-0432.CCR-08-2822
- Kukowska-Latallo JF, Candido KA, Cao Z, et al (2005). Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res, 65, 5317-24. https://doi.org/10.1158/0008-5472.CAN-04-3921
- Kurai J, Chikumi H, Hashimoto K, et al (2007). Antibodydependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res, 13, 1552-61. https://doi.org/10.1158/1078-0432.CCR-06-1726
- Lopez-Lazaro M (2008). Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Molecular Nutrition Food Resea, 52, 103-27.
- Migliore L, Coppede F (2002). Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Research/Reviews Mutat Res, 512, 135-53. https://doi.org/10.1016/S1383-5742(02)00046-7
- Nagle DG, Zhou YD, Mora FD, et al (2004). Mechanism targeted discovery of antitumor marine natural products. Current Med Chem, 11, 1725. https://doi.org/10.2174/0929867043364991
- Pankova V, El-Shafei MAE-A, El-Fotouh E-MA, et al (2014). Cytotoxicity of trichoderma spp. cultural filtrate against human cervical and breast cancer cell lines. Asian Pac J Cancer Prev, 15, 7229-34. https://doi.org/10.7314/APJCP.2014.15.17.7229
- Park E-H, Kim Y-J, Yamabe N, et al (2014). Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. J Ginseng Res, 38, 22-7. https://doi.org/10.1016/j.jgr.2013.11.007
- Pennati M, Lopergolo A, Profumo V, et al (2014). miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochemical Pharmacol, 87, 579-97. https://doi.org/10.1016/j.bcp.2013.12.009
- Rattan R, Graham RP, Maguire JL, et al (2011). Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia, 13, 483-28. https://doi.org/10.1593/neo.11148
- Sadikovic B, Al-Romaih K, Squire J, et al (2008). Cause and consequences of genetic and epigenetic alterations in human cancer. Current genomics, 9, 394. https://doi.org/10.2174/138920208785699580
- Schleich N, Sibret P, Danhier P, et al (2013). Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int J Pharmaceutics, 447, 94-101. https://doi.org/10.1016/j.ijpharm.2013.02.042
- Siegel RL, Miller KD, Jemal A (2015). Cancer statistics, 2016. CA: A cancer journal for clinicians.
- Vanneman M, Dranoff G (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer, 12, 237-51. https://doi.org/10.1038/nrc3237
- Wang HQ, Li DL, Lu YJ, et al (2013). Anticancer activity of Acanthopanax trifoliatus (L) Merr extracts is associated with inhibition of NF-kB activity and decreased Erk1/2 and Akt phosphorylation. Asian Pacific J Cancer Prev, 15, 9341-6.